ArticleFrontiers in oncology2025
Analysis of the diagnostic efficacy of ultrasound, MRI, and combined examination in benign and malignant breast tumors.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Monitoring Pharmacological Treatment of Breast Cancer with MRI.Current issues in molecular biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To compare the diagnostic effectiveness of ultrasound (US), magnetic resonance imaging (MRI), and their combined application in distinguishing between benign and malignant breast tumors, with particular emphasis on evaluating diagnostic performance in different breast densities-fatty breast tissue, where fat predominates, and dense breast tissue, which contains a significant amount of fibroglandular tissue. Materials and methods: A retrospective analysis was conducted on 185 patients with breast tumors, including 90 malignant and 95 benign cases. All patients underwent both US and MRI examinations within one week prior to surgery. The diagnostic accuracy of US, MRI, and their combined use in differentiating benign and malignant tumors was evaluated. Results: The combined examination demonstrated the highest area under the curve (AUC), sensitivity, and negative predictive value (NPV) (0.904, 90%, 90.4%), outperforming US (0.830, 73.3%, 78.6%) and MRI (0.897, 89.7%, 88.8%). DeLong test results revealed statistically significant differences in AUC between US and MRI, as well as between US and the combined examination (P < 0.05). However, the difference in AUC between MRI and the combined examination was not significant (P = 0.939). In patients with fatty breast tissue, no significant differences were found between MRI and US, or between MRI and the combined examination (P = 0.708 and P = 0.317, respectively). However, the diagnostic performance between US and the combined examination was statistically significant (P < 0.05). For patients with dense breast tissue, the differences in diagnostic performance between US and MRI, and between US and the combined examination, were significant (P < 0.05), while the difference between MRI and the combined examination was not significant (P = 0.317). Conclusion: MRI and combined examination methods significantly enhance the ability to differentiate benign and malignant breast tumors and provide important clinical value for early breast cancer detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.